PAVmed Inc. (NASDAQ:PAVM) Short Interest Down 65.0% in August

PAVmed Inc. (NASDAQ:PAVM) saw a large decrease in short interest in August. As of August 31st, there was short interest totaling 7,939 shares, a decrease of 65.0% from the August 15th total of 22,659 shares. Based on an average daily volume of 13,726 shares, the short-interest ratio is currently 0.6 days. Approximately 0.1% of the company’s shares are short sold.

Analyst Upgrades and Downgrades

A number of equities analysts recently commented on the stock. Ascendiant Capital Markets decreased their target price on shares of PAVmed from $65.00 to $56.00 and set a “buy” rating on the stock in a research report on Monday, June 8th. Weiss Ratings lowered shares of PAVmed from a “sell (d)” rating to a “sell (e+)” rating in a research report on Friday, August 14th. One investment analyst has rated the stock with a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat.com, the company has a consensus rating of “Hold” and a consensus price target of $56.00.

Institutional Investors Weigh In On PAVmed

Several institutional investors have recently added to or reduced their stakes in PAVM. BlackRock Inc. purchased a new position in shares of PAVmed in the second quarter valued at about $102,000. Jane Street Group LLC boosted its holdings in shares of PAVmed by 392.9% during the second quarter. Jane Street Group LLC now owns 52,676 shares of the company’s stock worth $32,000 after purchasing an additional 41,990 shares during the period. Geode Capital Management LLC grew its stake in shares of PAVmed by 74.8% in the fourth quarter. Geode Capital Management LLC now owns 168,832 shares of the company’s stock worth $40,000 after purchasing an additional 72,258 shares during the last quarter. Finally, Two Seas Capital LP bought a new stake in shares of PAVmed in the second quarter worth about $2,742,000. Hedge funds and other institutional investors own 19.93% of the company’s stock.

PAVmed Stock Performance

Shares of PAVM stock opened at $4.18 on Friday. The company has a debt-to-equity ratio of 0.98, a quick ratio of 1.19 and a current ratio of 1.19. PAVmed has a fifty-two week low of $3.85 and a fifty-two week high of $28.44. The stock has a 50 day moving average price of $5.12 and a two-hundred day moving average price of $6.91. The company has a market capitalization of $33.44 million, a P/E ratio of -0.26 and a beta of 0.53.

PAVmed Company Profile

PAVmed Inc is a clinical-stage medical technology company focused on acquiring, developing and commercializing innovative medical devices aimed primarily at gastrointestinal endoscopy and related therapeutic areas. Its portfolio includes FDA-cleared products such as EsoFLIP® Distensibility System for the treatment of esophageal strictures and MUSE™ (Medigus Ultrasonic Surgical Endostapler) for endoscopic fundoplication in gastroesophageal reflux disease (GERD). In addition to its gastrointestinal franchise, PAVmed is advancing early-stage programs targeting indications in oncology, urology and dermatology.

Founded in 2012, PAVmed has built its pipeline through internal research and development as well as strategic collaborations and acquisitions.